Flavoxate

Introduction Overview

Generic Name

flavoxate

Brand Name

Urispas

Dosage Form

Oral tablets

Drug Class

Urinary antispasmodics

Pharmacokinetics

Absorption:
Flavoxate demonstrates moderate to good oral absorption after administration. The drug is absorbed primarily through the gastrointestinal tract, allowing systemic availability sufficient for clinical efficacy in reducing urinary tract muscle spasms. Peak plasma concentrations are typically achieved within 1 to 2 hours post-dose. Absorption can be influenced by concomitant food intake, with some studies suggesting food may delay the time to peak concentration but does not significantly alter the overall extent of absorption. The bioavailability of flavoxate remains adequate for consistent therapeutic outcomes, although limited detailed pharmacokinetic studies exist to fully characterize interpatient variability.

Distribution:
Following absorption, flavoxate is widely distributed throughout the body, particularly to urinary tract tissues where it exerts its clinical effects. It has moderate protein binding in plasma, which influences its free active concentration. The drug penetrates bladder smooth muscle and urinary tract tissues with sufficient concentrations to inhibit muscarinic receptors and thus alleviate spasms. There is limited data on blood-brain barrier penetration, but the risk of central nervous system effects is considered low to moderate. Volume of distribution values reported support wide tissue penetration but are balanced by renal and hepatic elimination pathways.

Metabolism:
Flavoxate undergoes hepatic metabolism primarily via oxidative pathways mediated by cytochrome P450 enzymes. The metabolism produces several inactive or less active metabolites, which are then prepared for excretion. Hepatic function alterations can modulate the metabolism rate, necessitating caution or dose adjustment in patients with liver impairment. Phase I metabolic transformations are predominant with limited reports of conjugative phase II metabolism. Drug-drug interactions via CYP450 modulation are theoretically possible but not widely documented.

Elimination:
The elimination of flavoxate and its metabolites occurs predominantly through renal excretion. Both unchanged drug and metabolites are eliminated in urine, contributing to a clearance that is efficient to avoid accumulation in patients with normal renal function. The half-life ranges approximately from 4 to 8 hours, supporting a typical dosing interval of three to four times daily. In patients with renal impairment, altered clearance may occur, requiring clinical monitoring. Fecal elimination is considered minor. Understanding the elimination profile is critical in avoiding toxicity and optimizing therapeutic regimens.

Dosage Forms

Available Dosage Forms:
Urispas is available as oral tablets, typically in strengths formulated for adult dosing. The commonly manufactured dosage form is the film-coated oral tablet designed for ease of administration and consistent absorption.

Dosages for Adults and Adolescents:
The standard adult dose of flavoxate (Urispas) orally is 100 mg taken three to four times daily. Dosing adjustments may be necessary based on clinical response and tolerability. The medication is not approved for use in children under 12 years of age. Dose escalation should be avoided without medical supervision.

Specific Patient Populations:
The use of flavoxate in elderly patients should be cautious due to increased susceptibility to anticholinergic side effects such as confusion and blurred vision. Dosage adjustments may be required in patients with hepatic or renal impairment to prevent adverse effects and accumulation. Flavoxate is not approved for pediatric use under 12 years. Safety in pregnant or lactating women has not been fully established; although no expected harm has been observed, clinical decisions should weigh benefits versus potential risks. The drug should be used with caution in patients with glaucoma or urinary retention.

Mechanism Of Action

Urispas (flavoxate) functions primarily as a urinary antispasmodic agent by exerting a direct relaxant effect on the smooth muscle of the urinary bladder and urinary tract. Its principal mechanism involves blockade of muscarinic (M3) receptors on detrusor muscle cells, thereby inhibiting parasympathetic nervous system-mediated contractions which cause overactive bladder symptoms and urinary spasms. By blocking these receptors, flavoxate diminishes involuntary detrusor muscle contractions leading to relief of urinary urgency, frequency, and dysuria.

At the molecular level, flavoxate competes with acetylcholine at the muscarinic receptor sites, thereby preventing the activation of intracellular signaling cascades that induce calcium release and muscle contraction. This anticholinergic activity is selective enough to reduce urinary muscle spasms without substantially affecting other smooth muscle systems, although side effects consistent with anticholinergic blockade can occur.

Additionally, flavoxate exhibits phosphodiesterase inhibitory activity leading to increased intracellular cyclic AMP, which enhances smooth muscle relaxation. This dual mechanism potentiates its antispasmodic effects beyond simple receptor antagonism. Biochemical studies have shown modulation of calcium ion flux in muscle cells as part of its relaxing effect.

Clinically, these mechanisms translate into improved bladder compliance, decreased bladder pressure, and amelioration of symptoms such as painful urination, urinary urgency, frequency, and incontinence. Compared to other antimuscarinic agents like oxybutynin, flavoxate offers a distinct chemical structure, which may influence its side effect profile and tolerability. Research supports flavoxate's efficacy in treating overactive bladder symptoms as part of combination therapy or monotherapy, though it is no longer marketed under the U.S. trade name Urispas.

Pharmacological Actions

Direct smooth muscle relaxant effect on urinary bladder detrusor muscle
Muscarinic receptor (M3) antagonist reducing parasympathetic-induced contractions
Phosphodiesterase inhibition leading to increased cyclic AMP and smooth muscle relaxation
Inhibition of cholinergic transmission in the urinary tract musculature
Reduction of urinary bladder spasms and prevention of involuntary contractions
Relief of symptoms associated with overactive bladder including frequency and urgency
Reduction of bladder pain and dysuria by decreasing smooth muscle hyperactivity
Modulation of calcium ion flux in muscle cells contributing to antispasmodic effect
Minimal central nervous system penetration resulting in moderate CNS side effects
Potential to improve bladder compliance during filling phases
Dual mechanism combining muscarinic blockade and intracellular signaling modulation

Therapeutic Or Clinical Uses

Treatment of urinary bladder muscle spasms
Management of overactive bladder symptoms including urgency and frequency
Relief of painful urination (dysuria) associated with bladder muscle spasms
Treatment of increased nighttime urination (nocturia) caused by bladder overactivity
Reduction of urinary incontinence symptoms related to detrusor instability
Management of bladder symptoms caused by prostatism or prostate enlargement
Adjunctive therapy for bladder irritation due to infections or catheterization
Symptomatic relief of urinary urgency and frequency secondary to urethral irritation
Used off-label for bladder pain syndrome or interstitial cystitis in some cases
Supportive treatment for lower urinary tract disorders with a muscular spasm component
Dietary symptom management in patients where anticholinergic therapy is indicated

Side Or Adverse Effects

Nausea and vomiting
Dry mouth due to anticholinergic effects
Headache and dizziness
Drowsiness or sedation impairing alertness
Pounding or fluttering heartbeat (palpitations)
Confusion and nervousness, especially in elderly patients
Allergic skin reactions such as rash or itching
Blurred vision secondary to anticholinergic blockade of ocular muscles
Urinary retention particularly in patients with pre-existing obstruction
Constipation caused by smooth muscle relaxation of the gastrointestinal tract
Potential worsening of glaucoma symptoms due to pupillary dilation
Rare hypersensitivity reactions including angioedema
Central nervous system side effects including insomnia or agitation
Dry eyes and decreased sweating as peripheral anticholinergic effects
Occasional worsening of cognitive function in susceptible individuals

Precautions

Use cautiously in patients with glaucoma due to risk of increased intraocular pressure
Monitor patients with urinary retention or bladder outlet obstruction closely
Avoid use in individuals with gastrointestinal tract obstructions or bleeding
Exercise caution in elderly patients due to heightened risk of confusion and sedation
Assess liver and renal function prior to initiation and periodically during therapy
Avoid use or adjust dose in patients with impaired hepatic or renal function
Inform patients about potential dizziness and advise caution when driving or operating machinery
Consider pregnancy and breastfeeding status; use only if benefits outweigh risks
Avoid abrupt discontinuation without consulting healthcare provider
Laboratory monitoring for urinary function or adverse effects may be required
Evaluate concomitant medications to avoid additive anticholinergic burden
Counsel patients on recognizing signs of allergic reactions and to seek immediate care
Ensure full course of any prescribed antibiotics for urinary infections despite symptom improvement
Avoid use in children under 12 years due to lack of safety and efficacy data
Continually evaluate therapeutic effectiveness and the emergence of side effects

Warnings

Contraindicated in patients with bleeding disorders of the stomach or intestines
Not to be used in presence of gastrointestinal tract obstruction or gastric retention
Should not be given to patients with bladder obstruction or inability to urinate
Risk of exacerbation of urinary retention with use in susceptible patients
May cause blurred vision and impaired mental alertness; caution when driving
Potential for serious allergic reactions including anaphylaxis
Use with caution in patients with history of hypersensitivity to flavoxate or similar compounds
Not approved for pediatric use; safety in children below 12 years not established
Potential interactions with other anticholinergic drugs leading to additive side effects
Patients should be monitored for rare but serious cardiovascular side effects such as palpitations
Careful use recommended in elderly to prevent cognitive impairment or falls
Avoid use during lactation unless clearly necessary and after physician consultation
Long-term safety data limited; periodic evaluation of therapy is advised
Potential for CNS adverse effects particularly with concomitant CNS depressants
Overdose can cause atropine-like toxic effects requiring emergency management

Contraindication

Known hypersensitivity to flavoxate or any formulation excipients
Presence of gastrointestinal bleeding or significant obstruction in the GI tract
Diagnosis of bladder outlet obstruction or inability to voluntarily urinate
History of urinary retention disorders exacerbated by anticholinergic therapy
Patients with narrow-angle glaucoma or uncontrolled glaucoma
Severe hepatic or renal impairment without appropriate dose adjustments
Pediatric patients under 12 years of age due to lack of safety data
Concurrent use with other drugs that could precipitate urinary retention
Active urinary tract infections requiring antibiotic therapy (Urispas does not treat infection)
Conditions where anticholinergic effects pose significant risk such as myasthenia gravis
Patients with tachyarrhythmias or unstable cardiac conditions
Pregnant women unless the potential benefits outweigh the risks
Known mechanical obstruction of the urinary or gastrointestinal tracts
Severe ulcerative colitis or toxic megacolon
Patients with severe cognitive impairment prone to anticholinergic-related confusion

Drug Interactions

Additive anticholinergic effects when used with other antimuscarinic agents increasing risk of side effects
Potential interaction with CNS depressants such as benzodiazepines and alcohol leading to enhanced sedation
Concurrent use with drugs that inhibit cytochrome P450 enzymes may alter flavoxate metabolism
Use caution with other medications causing urinary retention such as tricyclic antidepressants
Possible increased risk of dry mouth, constipation, and blurred vision with antihistamines
Drugs affecting hepatic enzyme activity may alter plasma levels of flavoxate
No significant interaction reported with antibiotics but caution advised when co-administered
Careful monitoring required when combined with beta-3 adrenergic agonists used for overactive bladder
Additive cardiovascular effects may occur with sympathomimetic agents increasing heart rate
Caution advised when taken with potassium supplements or diuretics due to electrolyte imbalance risk
May interact with drugs affecting urinary pH altering excretion rate
Concurrent use with monoamine oxidase inhibitors (MAOIs) not well studied but requires caution
Herbal supplements with anticholinergic properties may potentiate flavoxate adverse effects
No major interactions reported with vitamins but all supplements should be disclosed to healthcare provider
Pharmacokinetic interaction potential is low but clinical monitoring during polypharmacy is recommended

Preparations Of The Drug

Urispas oral tablets in 100 mg strength
Generic flavoxate oral tablets available following U.S. discontinuation of brand
Film-coated tablets designed for oral administration and ease of swallowing
Packaged in blister packs or bottles depending on manufacturer
Available in formulations for adult dosages only; no pediatric-specific formulations
No injectable or topical formulations available for flavoxate
Stable at room temperature; should be stored away from moisture and light
Over-the-counter availability is generally limited; prescription required
Formulations contain inactive excipients such as lactose, magnesium stearate, and cellulose
No extended-release or sustained-release versions widely marketed
Manufactured by multiple generic pharmaceutical companies globally
Available as brand or generic depending on regional regulatory approvals
Packaging typically includes patient information leaflets and dosage instructions
Plain gelatin capsules are not typical; tablet form preferred for dose accuracy
No combination products with other urinary agents commonly available